Cargando…
Immunomodulatory properties of CD38 antibodies and their effect on anticancer efficacy in multiple myeloma
BACKGROUND: CD38 has been established as an important therapeutic target for multiple myeloma (MM), for which two CD38 antibodies are currently approved—daratumumab and isatuximab. CD38 is an ectoenzyme that degrades NAD and its precursors and is involved in the production of adenosine and other met...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652336/ https://www.ncbi.nlm.nih.gov/pubmed/37840445 http://dx.doi.org/10.1002/cam4.6619 |